Remix Therapeutics Inc. is getting $30 million up front in a potential $1 billion agreement with Roche AG aimed at developing small-molecule therapies designed to modulate RNA processing. The deal, ...
The c-MYB oncogene plays a key role in hematopoietic cell differentiation and proliferation. Genetic abnormalities and dysregulation of MYB have been found in several cancers, including adenoid cystic ...
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results